

## UNDERTAKING

**TO: Alberta Securities Commission, British Columbia Securities Commission, Financial and Consumer Affairs Authority (Saskatchewan), Manitoba Securities Commission, New Brunswick Securities Commission, Newfoundland Securities Commission, Nova Scotia Securities Commission, Ontario Securities Commission, and Prince Edward Island Securities Office (collectively, the “Commissions”)**

**RE: Medexus Pharmaceuticals Inc. (the “Issuer”) – Short Form Prospectus dated October 2, 2023 (the “Prospectus”)**

---

In accordance with Section 4.2(a)(x) of National Instrument 44-101 – *Short Form Prospectus Distributions* (“NI 44-101”), the Issuer hereby undertakes to file with the Commissions, a copy of any applicable:

- (a) material contract required to be filed under section 12.2 of National Instrument 51-102 – *Continuous Disclosure Obligations* (“NI 51-102”); and
- (b) agreement or contract affecting the rights of securityholders that relates to securities being distributed under the Prospectus required to be filed under subsection 12.1(1) of NI 51-102,

that has not been previously filed, and has not been executed before the filing of the Prospectus but will be executed on or before the completion of a distribution of securities under the Prospectus, promptly and in any event no later than seven days after the execution of the applicable agreement or contract.

In accordance with Section 4.2(a)(x.1) of NI 44-101, the Issuer hereby undertakes to file with the Commissions any document affecting the rights of securityholders that relates to securities being distributed under the Prospectus required to be filed under subsection 12.1(1) of NI 51-102 that has not been previously filed, and does not need to be executed in order to become effective and has not become effective before the filing of the Prospectus, but will become effective on or before the completion of a distribution of securities under the Prospectus, promptly and in any event no later than seven days after the applicable document becomes effective.

*[Remainder of page intentionally left blank]*

**DATED** this 2<sup>nd</sup> day of October, 2023.

**MEDEXUS PHARMACEUTICALS INC.**

By: (signed) “Ken d’Entremont”  
Name: Ken d'Entremont  
Title: Chief Executive Officer